A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study

Acceptance of healthcare-associated pneumonia (HCAP) as an entity and the associated risk of infection by potentially multidrug-resistant (MDR) organisms such as methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and Acinetobacter have been debated. We therefore compared patients with H...

Full description

Saved in:
Bibliographic Details
Published in:BMC infectious diseases 2013-11, Vol.13 (1), p.561-561, Article 561
Main Authors: Quartin, Andrew A, Scerpella, Ernesto G, Puttagunta, Sailaja, Kett, Daniel H
Format: Article
Language:English
Subjects:
Acetamides - therapeutic use
Acinetobacter
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Bacteria - classification
Bacteria - genetics
Bacteria - isolation & purification
Bacterial pneumonia
Comorbidity
Complications and side effects
Cross infection
Cross Infection - drug therapy
Cross Infection - epidemiology
Cross Infection - microbiology
Demographics
Demography
Drug dosages
Drug resistance in microorganisms
Ethics
Female
Geography
Health aspects
Health facilities
Hospital patients
Hospitalization
Hospitals
Humans
Linezolid
Male
Microbiology
Middle Aged
Mortality
Nosocomial infections
Nursing homes
Ostomy
Oxazolidinones - therapeutic use
Parenteral nutrition
Pharmaceutical industry
Pneumonia
Pneumonia, Ventilator-Associated - drug therapy
Pneumonia, Ventilator-Associated - epidemiology
Pneumonia, Ventilator-Associated - microbiology
Pseudomonas aeruginosa
Retrospective Studies
Review boards
Risk Factors
Staphylococcal infections
Staphylococcus aureus
Staphylococcus infections
Studies
Vancomycin - therapeutic use
Ventilation
Ventilators
Wound healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acceptance of healthcare-associated pneumonia (HCAP) as an entity and the associated risk of infection by potentially multidrug-resistant (MDR) organisms such as methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and Acinetobacter have been debated. We therefore compared patients with HCAP, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) enrolled in a trial comparing linezolid with vancomycin for treatment of pneumonia. The analysis included all patients who received study drug. HCAP was defined as pneumonia occurring
ISSN:1471-2334
1471-2334
DOI:10.1186/1471-2334-13-561